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ABSTRACT 
The strength of the DNA damage checkpoint critically influences cell fate, yet the 
mechanisms behind the fine tuning of checkpoint strength during the DNA damage 
response (DDR) are poorly understood. Here, we show that Rad54B — a SNF2 
helicase-like DNA-repair protein — limits the strength of both the G1/S and G2/M 
checkpoints. We find that Rad54B functions as a scaffold for p53 degradation via its 
direct interaction with the MDM2-MDMX ubiquitin-ligase complex. During the early 
phases of the DDR, Rad54B is upregulated, thereby maintaining low checkpoint 
strength and facilitating cell cycle progression. Once the p53-mediated checkpoint is 
established, Rad54B is downregulated, and high checkpoint strength is maintained. 
Constitutive upregulation of Rad54B activity, which is frequently observed in tumors, 
promotes genomic instability due to checkpoint override. Thus, the scaffolding function 
of Rad54B dynamically regulates the maintenance of genome integrity by limiting 
checkpoint strength.
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INTRODUCTION 
DNA damage responses (DDRs) play critical roles in maintenance of homeostasis, as 
exemplified by the findings that diverse human diseases, including cancer, are caused 
by deficiencies in DDR components1. The response to DNA double-strand breaks 
(DSBs) consists of both positive and negative regulatory pathways, which transmit their 
signals from sensors to effectors to execute cellular responses. These pathways are 
composed of proteins involved in post-translational modification, such as 
phosphorylation and ubiquitination. Accumulating evidence suggests that scaffold-like 
proteins, such as those harboring BRCT domains2, are involved in the signal 
transduction pathways of DDRs by recruiting various components and regulators. A 
recent study has revealed that DNA repair scaffolds directly modulate the checkpoint 
signaling pathway in budding yeast3. Therefore, the functions of scaffold-like proteins 
in the DDR play essential roles in the coordination of cellular responses to maintain 
homeostasis. 
Human Rad54B was initially identified as a homolog of human Rad54, a 
central effector of homologous recombination (HR), and mutations in its gene have 
been observed in primary cancers4. Rad54B and Rad54 belong to a subfamily of 
double-stranded DNA-dependent ATPases referred to as the SWI2/SNF2 family, which 
is characterized by conserved helicase-like sequence motifs5. Although previous studies 
suggested that Rad54B plays roles in the HR and DNA repair processes6,7,8,9, 
biochemical analysis has shown that Rad54B is a less active DNA-dependent ATPase 
than Rad5410. In addition, in contrast to Rad54, the ATPase activity of Rad54B is not 
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enhanced by the presence of Rad51 and single-stranded DNA. These observations led 
us to hypothesize that Rad54B plays unknown roles aside from HR repair. 
During the cellular response to DNA damage, the choice between cell cycle 
arrest and progression is critical to the determination of the cell fate. However, despite 
the importance of the choice, the mechanisms by which this choice is modulated are 
poorly understood. Here, we show that the SNF2-like domain of Rad54B serves as a 
scaffold for p53 degradation by facilitating MDM2-MDMX-mediated ubiquitination. 
Rad54B, whose levels are dynamically regulated in response to DNA damage, regulates 
the choice between cell cycle arrest and progression by fine-tuning the expression levels 
of p53. These data suggest that the scaffolding function of Rad54B plays an essential 
role in the coordination of cellular responses after DNA damage. 
 
RESULTS 
Rad54B is a novel DNA damage-responsive protein 
First, we examined how Rad54B levels are regulated during the DDR. We found that 
the levels of Rad54B dynamically changed in response to the genotoxic stresses (Fig. 1a 
and Supplementary Fig. 1a). Because it appeared that the change in the levels of 
Rad54B negatively correlated to those of p53, we examined whether p53 is involved in 
the regulation of the Rad54B levels. Rad54B was transcriptionally suppressed by p53 at 
a late time point after DNA damage (Fig. 1b). In addition, the Rad54B protein and 
mRNA levels were suppressed by Nutlin-3-mediated p53 induction (Fig. 1c), 
suggesting that this transcriptional repression mechanism was independent of p53 
 5 
modification upon DNA damage. Some p53-repressed targets are regulated by the 
cyclin–dependent kinase inhibitor p2111. However, the repression of Rad54B by p53 
was not mediated by p21 (Supplementary Fig. 1b). 
To investigate the mechanism underlying Rad54B induction at early time 
points after DNA damage, we analyzed cell lines that lack functional p53 (HT-29 and 
H1299). Although the decreases in Rad54B expression at the late time points were not 
observed in these cell lines, Rad54B expression was significantly increased at the 
transcriptional level at the early time points (Figs. 1d,e and Supplementary Figs. 1c-e). 
We also found that this induction of Rad54B expression was independent of the activity 
of ATM, although the timing of this induction appeared to be delayed by ATM 
inhibition (Fig. 1f and Supplementary Fig. 1f). Thus, Rad54B is transcriptionally 
induced during the early phases of the DDR independently of the activity of ATM and 
is transcriptionally repressed as the p53 levels increase. 
 
Rad54B suppresses the p53 levels independently of ATM 
Although previous studies suggest that Rad54B plays roles in the HR and DNA repair 
processes6,7, we found a completely novel function of Rad54B; Rad54B suppressed the 
p53 levels and functions in the steady state independently of the activity of ATM (Figs. 
1g,h and Supplementary Figs. 1g,h). Although MDM2 is a well-characterized negative 
regulator of p53, p53 upregulation was detected even though MDM2 was upregulated 
(Supplementary Fig. 1g), suggesting that MDM2 does not efficiently act as a negative 
regulator of p53 in the absence of Rad54B. Rad54B repressed the p53 levels and 
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functions even after the genotoxic stresses, which was also independent of the ATM 
activity (Figs. 1i,j and Supplementary Figs. 2a-c). Interestingly, the levels of 
phosphorylated p53 were increased in Rad54B-knockdown cells in parallel with the p53 
upregulation, whereas the upstream DDRs were not enhanced (Supplementary Fig. 2d). 
Furthermore, the amount of DNA damage during the DDR upon oxaliplatin treatment, 
as measured by focus formation of γH2AX or 53BP1, was not affected by Rad54B 
inhibition (Fig. 1k and Supplementary Fig. 2e). Thus, our data suggest that Rad54B 
inhibition upregulates the p53 levels and functions without increasing the amount of 
DNA damage. One previous study reported apparently contradictory results regarding 
the activity of p53 in Rad54/Rad54b double-knockout cells12. However, the findings of 
Mahabir et al. do not contrast with our results due to differences in the genotype of the 
cells used and in the experimental conditions, particularly the level of DNA damage 
induced. In their study, the treated cells exhibited 80% survival, whereas in our study, 
the treated cells exhibited 10% or less survival.  
The stability of the p53 protein was dramatically increased by Rad54B 
knockdown (Fig. 1l and Supplementary Fig. 3a). In addition, we detected a reduction in 
endogenous p53 ubiquitination in Rad54B-knockdown cells (Fig. 1m and 
Supplementary Fig. 3b). One known mechanism by which p53 is stabilized involves the 
alteration of the localization of the negative regulator MDM2 from the nucleus to the 
nucleolus13. We found that the MDM2 localization pattern, i.e., localization 
predominantly in the nucleoplasm and very low expression in the nucleolus or 
cytoplasm, was not altered by Rad54B knockdown (Supplementary Fig. 3c). Another 
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mechanism by which p53 is stabilized is the destabilization of the p53-MDM2 
complex14. We found that the amount of MDM2 that co-immunoprecipitated with p53 
was not reduced by Rad54B knockdown (Supplementary Fig. 3d). These data suggested 
that Rad54B regulates p53 via an alternative mechanism. Previous studies reported that 
MDMX augments the E3 ligase activity of MDM2 by forming a heterodimer with 
MDM215,16. We examined MDM2-MDMX heterodimer formation in 
Rad54B-knockdown cells. The amount of MDMX that bound to MDM2 was reduced 
by Rad54B knockdown, even after oxaliplatin treatment (Fig. 1n and Supplementary 
Figs. 3e,f), indicating that Rad54B regulates the heterodimerization between MDM2 
and MDMX, thereby enhancing its ubiquitin ligase activity on p53, which we designate 
the Rad54B-p53 axis. Therefore, Rad54B appears to enhance the ubiquitin ligase 
activity of MDM2 on p53 by promoting MDM2-MDMX heterodimerization and 
counteracts the ATM-mediated positive regulation of p53 (Fig. 1o). 
 
Rad54B directly interacts with MDM2 and MDMX 
To clarify how Rad54B promotes MDM2-MDMX heterodimerization, we examined 
whether Rad54B interacts with MDM2 and MDMX. Exogenous Rad54B interacted 
with exogenous MDM2 and MDMX in Cos7 cells (Figs. 2a,b). In addition, an 
interaction between endogenous Rad54B and MDM2 was detected in several human 
cell lines, including the p53-inactive cell line HeLa (Fig. 2c and Supplementary Figs. 
4a,b), indicating that Rad54B and MDM2 universally form a complex independent of 
the p53 status. We detected an interaction between endogenous Rad54B and MDMX 
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only in the nuclear extract after proteasome inhibition, suggesting that the 
Rad54B-MDMX complex exists only transiently in the nucleus (Supplementary Fig. 4c). 
The findings that MDM2 knockdown does not affect the levels of Rad54B, as shown 
above (Supplementary Fig. 1g), and that Rad54B is not a substrate of proteasomal 
degradation (Supplementary Fig. 4d) indicate that the MDM2-Rad54B interaction does 
not reflect an enzyme-substrate interaction. 
Next, we identified the domains responsible for these interactions. Rad54B is 
primarily composed of three domains (Fig. 2d). In Cos7 cells, SNF2-1 was responsible 
for the interaction between Rad54B and both MDM2 and MDMX (Figs. 2e,f). 
Furthermore, the SNF2-1 protein was pulled down with the GST-MDM2 or 
GST-MDMX protein but not with GST alone (Fig. 2g), indicating that the 
Rad54B-MDM2 and Rad54B-MDMX interactions are direct. This domain of Rad54B is 
characterized by a DExH-box helicase motif and a Walker A nucleotide-binding motif4. 
Although this domain is well conserved among the members of the SWI2/SNF2 family, 
including Rad54, Rad54 did not interact with MDM2 (Supplementary Fig. 4e). Our next 
interest was to determine whether the ATPase activity of Rad54B plays any role in the 
Rad54B-p53 axis. Interestingly, the DExH-box domain of Rad54B (SNF2-1) alone was 
sufficient to downregulate p53 (Figs. 2h,i). The crystal structure studies of the 
SWI2/SNF2 helicase-like domains of Sulfolobus solfataricus Rad54 (SsoRad54) and 
zebrafish Rad54 revealed that the N-terminal half of the SWI2/SNF2 helicase-like 
domain (DExx-box domain) faces the C-terminal half of the SWI2/SNF2 helicase-like 
domain (HELICc domain)17,18. Furthermore, mutations in each domain have been 
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shown to affect the double-stranded DNA-dependent ATPase activity of SsoRad54, 
indicating that both the DExx-box and HELICc domains are required for its catalytic 
activity17. Therefore, the result shown in Fig. 2i suggests that Rad54B likely regulates 
p53 in an ATPase activity-independent manner. Thus, the DExH-box domain of 
Rad54B not only contributes to the ATPase activity but also functions as an interface 
for protein-protein interaction. 
MDM2 is composed of four domains (Fig. 2j). With respect to the 
Rad54B-binding site in MDM2, deletion of the p53-binding domain, the zinc finger 
domain, and the RING finger domain did not affect the interaction between MDM2 and 
Rad54B, but deletion of the acidic domain caused a loss of the interaction (Fig. 2k). 
Therefore, the acidic domain in MDM2 is responsible for its interaction with Rad54B. 
Some MDM2 binding partners, such as ARF and YY1, are known to bind to this 
domain and participate in the negative regulation of p53. However, as shown above 
(Supplementary Figs. 3c,d), the mechanism underlying the negative regulation of p53 
by Rad54B is distinct from that by ARF or YY1. 
Because exogenous MDMX expression in cells is known to produce some 
artifactual results19, we identified the Rad54B-binding site in MDMX by pull-down 
assays (Supplementary Fig. 4f). MDMX primarily consists of four domains (Fig. 2l). 
We identified two Rad54B-binding sites located in the N-terminus of MDMX, one of 
which is the p53-binding domain (Fig. 2m). These data suggest that Rad54B can bind to 
MDMX independent of p53. 
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Rad54B serves as a scaffold for MDM2-MDMX heterodimerization 
To determine whether the Rad54B-MDM2 and Rad54B-MDMX interactions are 
sufficient for the mechanism underlying the Rad54B-p53 axis, we performed an in vitro 
ubiquitination assay using recombinant proteins. Consistent with previous reports, 
MDMX enhanced the p53 polyubiquitination activity of MDM2 in vitro (Fig. 3a, lanes 
2, 4). Moreover, p53 polyubiquitination was further enhanced by adding SNF2-1 in 
addition to MDMX (Fig. 3a, lanes 3-5), indicating that Rad54B plays a role in the 
regulation of p53 polyubiquitination by stimulating MDM2-MDMX heterodimerization 
and ligase activity.  
Next, we investigated the detailed properties of each complex by pull-down 
assays to further elucidate the relationship between Rad54B and the MDM2-MDMX 
heterodimer. As shown in Fig. 3b, when the three components GST-MDMX, MDM2, 
and SNF2-1 were added to the reaction simultaneously, the amount of MDM2 binding 
to GST-MDMX was not increased but rather was reduced, likely because SNF2-1 binds 
to both MDM2 and MDMX, thereby disturbing the formation of the MDM2-MDMX 
heterodimer. This result suggests that excess SNF2-1 disturbs MDM2-MDMX 
heterodimerization by preferentially forming complexes with both MDM2 and MDMX. 
In contrast, when MDMX was added after allowing MDM2-SNF2-1 complex formation, 
MDMX efficiently bound to MDM2 (Fig. 3c). These data suggest that Rad54B serves 
as a scaffold for MDM2-MDMX heterodimerization by recruiting MDMX to MDM2 
and facilitates efficient p53 degradation (Fig. 3d). 
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Rad54B promotes mutagenic adaptation to the G2/M checkpoint 
To determine the relevance of Rad54B-mediated p53 regulation in cell fate 
determination after DNA damage, we investigated the cell cycle distribution after 
induction of DNA damage. We found that the number of cells in the G2/M phase was 
increased in RAD54B knockout (KO) HCT116 cells after oxaliplatin treatment (Fig. 4a) 
and in RAD54B KO HCT116 and Rad54B-knockdown A549 cells after ionizing 
radiation (IR) (Supplementary Figs. 5a,b). In addition, we confirmed that the phenotype 
of increased G2/M arrest in RAD54B KO cells was rescued by introducing 
GFP-conjugated Rad54B (Fig. 4b and Supplementary Fig. 5c). Interestingly, the 
increase in G2/M-arrested RAD54B KO cells after oxaliplatin treatment was dependent 
on the p53 levels (Fig. 4c). These findings indicated that the G2/M checkpoint strength 
is reduced by the Rad54B-p53 axis. Notably, aneuploidy was increased by oxaliplatin 
treatment in wild-type HCT116 cells (Fig. 4a). In addition, the number of RAD54B KO 
cells in sub-G1 was decreased after oxaliplatin treatment (Fig. 4a). We confirmed that 
this result was due to a reduction in apoptotic cells (Supplementary Fig. 5d). Therefore, 
because most RAD54B KO cells are strongly arrested at the G2 phase, aneuploidy or 
apoptosis arising after release from this arrest appears to be decreased.  
As for inactivation of the G2/M checkpoint, previous studies showed that some 
cells with unrepaired DNA damage escape from the G2/M checkpoint and enter the next 
cell cycle phase. This process of overriding the G2/M checkpoint, referred to as 
adaptation, was first described in Saccharomyces cerevisiae20 and was recently 
observed in higher eukaryotes, including Xenopus cells21 and even human cancer cells22. 
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Thus, we examined whether the Rad54B-dependent abrogation of the G2/M checkpoint 
observed in wild-type HCT116 cells was accompanied with the cells which undergo 
adaptation. First, as shown in Fig. 4d, the number of RAD54B KO cells that underwent 
G2/M transition from 12 to 24 hours after oxaliplatin addition was significantly reduced, 
consistent with the results in Fig. 4a, and this phenotype was rescued by p53 
knockdown (Fig. 4e). Next, we examined whether the G2/M transition observed in 
wild-type cells was accompanied with DNA damage. Surprisingly, approximately 30% 
to 40% of the wild-type cells in mitosis displayed rigid γH2AX foci when treated with 
oxaliplatin (Fig. 4f). Furthermore, we found that adaptation was frequently 
accompanied by chromosomal fragmentation (Fig. 4g). Such fragmentation is highly 
mutagenic because it can lead to micronucleus formation and loss or translocation of 
chromosomes. These data suggest that the absolute number of cells which undergo 
adaptation is increased by Rad54B-mediated inactivation of the G2/M checkpoint. 
Overall, our data suggest that Rad54B induces highly mutagenic chromosome 
instability by promoting adaptation. 
 
Rad54B limits the strength of the G1/S checkpoint  
Next, we assessed cell morphology after treatment with genotoxic drugs for 
approximately one week (Fig. 5a). After oxaliplatin treatment, the RAD54B KO cells 
were more likely to remain attached to the dish without any appearance of cell division. 
5-FU treatment produced similar results, except that evident and countable colonies 
were not formed after 5-FU treatment. Based on this finding, we hypothesized that 
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Rad54B regulates the strength of the G1/S checkpoint as well as that of the G2/M 
checkpoint. Indeed, the strength of the G1/S checkpoint after 5-FU or oxaliplatin 
treatment was increased by RAD54B KO in HCT116 cells (Fig. 5b and Supplementary 
Fig. 6a) and by Rad54B knockdown in LoVo cells (Supplementary Fig. 6b), which 
appeared to be partially attributed to the upregulation of the cyclin-dependent kinase 
inhibitor p21 (Supplementary Fig. 6c). Notably, aneuploidy was increased by 5-FU 
treatment in wild-type HCT116 cells (Fig. 5b). Furthermore, we detected a decrease in 
the intake of nucleotides in RAD54B KO cells approximately 48 hours after the 
initiation of 5-FU treatment (Supplementary Fig. 6d). Importantly, the phenotype of the 
decrease in the number of S-phase cells was rescued by p53 knockdown in RAD54B KO 
cells (Fig. 5c), suggesting that the Rad54B-p53 axis plays critical roles in the regulatory 
mechanism responsible for inactivation of the G1/S checkpoint. 
Proliferation under DNA-damaged conditions increases the probability of 
genomic instability and mutagenesis. Thus, we examined the impact of Rad54B 
overexpression on the normal cell line RPE and found that Rad54B overexpression 
reduced the p53 levels after 5-FU or oxaliplatin treatment (Supplementary Figs. 6e,f). 
Furthermore, the number of G1-arrested RPE cells after either 5-FU or oxaliplatin 
treatment was reduced by introduction of the GFP-Rad54B protein (Figs. 5d,e). These 
data suggest that Rad54B overexpression in normal cells limits the G1/S checkpoint 
strength, thereby promoting cell cycle progression under DNA-damaged conditions. 
To further investigate the roles of Rad54B in the G1/S transition, we examined 
cells synchronized in the G0/G1 phase by serum starvation or contact inhibition. As 
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expected, cell cycle progression after IR was delayed in G0/G1 phase-synchronized 
RAD54B KO HCT116 and Rad54B-knockdown RPE cells (Figs. 5f,g and 
Supplementary Fig. 6g). Furthermore, the G1/S checkpoint strength after IR was 
dependent on the p53 levels (Fig. 5h), supporting our hypothesis that the Rad54B-p53 
axis plays a critical role in the G1/S checkpoint strength. 
 
Rad54B is a possible therapeutic target for cancer 
Based on in vitro colony formation assays, we found that the wild-type cells formed 
more colonies than the RAD54B KO cells (Fig. 6a). These data suggest that the 
reduction of the checkpoint strength by Rad54B confers a chance of long-term cell 
survival. To investigate this effect in vivo, we employed a xenograft model using nude 
mice. The RAD54B KO cell-derived xenografts grew more slowly than the wild-type 
cell-derived xenografts after either oxaliplatin or 5-FU treatment (Fig. 6b). Furthermore, 
the number of S-phase cells was reduced in RAD54B KO cell-derived xenografts 
compared to the wild-type cell-derived xenografts (Fig. 6c), suggesting that G1/S 
checkpoint regulation affects xenograft growth. Therefore, Rad54B inhibition enhances 
the sensitivity of tumor to genotoxic drugs.  
Finally, we investigated the contribution of Rad54B to the neoplastic process. 
We selected datasets from the Gene Expression Omnibus database provided by NCBI 
(http://www.ncbi.nlm.nih.gov/geo/) and used these data to compare the expression 
levels of Rad54B between normal and tumor samples. As shown in Fig. 6d, Rad54B 
expression was elevated in many different types of solid tumors. In addition, the two 
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datasets that provided paired expression data between normal and neoplastic samples 
from the same patient revealed that all of the samples from colorectal adenoma and 80% 
of the samples from lung squamous carcinoma displayed elevated Rad54B expression 
(Fig. 6e and Supplementary Table 1). Notably, enhanced Rad54B expression was 
observed even in the early stage of the neoplastic process. Furthermore, brain tumor 
patients displaying elevated Rad54B expression exhibited extremely poor prognosis 
according to the Kaplan-Meier curve analysis using the REpository for Molecular 
BRAin Neoplasia DaTa (REMBRANDT) (Fig. 6f; 
http://caintegrator.nci.nih.gov/rembrandt/). Therefore, these results suggested that 
elevated Rad54B expression exacerbates clinical outcomes. 
Our model shown above suggests that the association between elevated 
Rad54B expression and the neoplastic process may be dependent on p53 protein 
function. However, unfortunately, none of the above databases includes any information 
regarding the mutation status. Therefore, according to a previous study23, we predicted 
the mutation status of the samples based on their gene expression patterns, as described 
in detail in the Methods section. We examined breast cancer (GDS2250), colon 
adenoma (GDS2947), and glioblastoma (REMBRANDT) samples and found no 
significant association between the predicted p53 status and the Rad54B expression 
pattern (Supplementary Figs. 7-9, Supplementary Tables 2 and 3). Overall, these 
database analyses indicate that the Rad54B-p53 axis plays critical roles in the neoplastic 
overprocess. 
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Discussion 
Upon DNA damage, the sequential recruitment and activation of the DDR proteins 
ensure the proper choice of cell fate1. The timing of activation of each DDR protein 
varies from a few minutes to a few days after DNA damage. For example, the 
recruitment of the DNA-damage marker γH2AX peaks within a few hours after DNA 
damage, whereas the accumulation of p53 peaks at later time points. Therefore, it has 
been assumed that negative-regulatory mechanisms for the DDR during its early phases 
play a role in the coordination of cellular responses24. In this study, we demonstrated 
that the DNA damage-responsive scaffold protein Rad54B constitutes the 
ATM-independent negative-regulatory DDR pathway; Rad54B is upregulated during 
the early phases of the DDR to limit p53 activation and is downregulated during the late 
phases of the DDR to stably induce p53-mediated responses (Fig. 1o). This 
transcription- and ubiquitination-dependent signaling, in parallel with the 
phosphorylation-mediated signaling regulated by ATM, causes the latency of 
p53-mediated checkpoint activation (Fig. 7a). Imbalanced upregulation of Rad54B 
function promotes genomic instability via G1/S checkpoint override and adaptation to 
the G2/M checkpoint (Fig. 7b). Our discovery of this exquisite mechanism of p53 
regulation via the scaffolding function of Rad54B provides the potential for a novel 
cancer therapy. Inhibition of Rad54B upregulates the p53 levels without increasing 
apoptosis even after treatment with genotoxic drugs (Supplementary Fig. 10). In 
addition, we emphasized the potential advantages of Rad54B inhibition-mediated 
therapy for targeting tumors at the earlier stages of the neoplastic process (Figs. 5d,e, 
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and 6e). Thus, Rad54B inhibition, in combination with administration of 
DNA-damaging agents, may represent a feasible intervention for p53-reactivating 
cancer therapy.  
 Although the association between the checkpoint strength and cellular 
consequences is complex, we assumed that it primarily depends on the type of DNA 
damage. As shown in this study, Rad54B broadly limits the checkpoint strength 
regardless of the cell type and the type of DNA damage (Figs. 4a, 5b,d-g, 
Supplementary Figs. 5a,b, and 6b). On the other hand, the long-term cell survival rate 
varies depending on the type of DNA damage; RAD54B KO cells are slightly resistant 
to IR6, but they are sensitive to oxaliplatin or 5-FU treatment (Fig. 6a-c). Cell cycle 
progression under DNA-damaged conditions results in cell death in most cases, but in 
some cases, it confers a chance of cell survival. These contradicting aspects of cell cycle 
progression after DNA damage appear to explain these apparently contradicting results. 
As for the biological significance of limiting the checkpoint strength, we speculated that 
some types of DNA damage, such as that caused by an imbalance of the nucleotide pool 
or DNA cross-linking, might not be repaired during checkpoint arrest because such 
“potential” DNA damage does not manifest until the cell cycle progresses to 
proliferative phases. Therefore, the repair protein Rad54B likely contributes to the 
mechanism for cell cycle progression to enable this dormant damage to manifest and to 
be repaired. Overall, the scaffolding function of Rad54B, by limiting the checkpoint 
strength, coordinates cell fate determination during the DDR. 
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METHODS 
Cell culture and antibodies 
All cell lines were cultured in a 37°C incubator at 5% CO2. The A549 and RPE cells 
were obtained from RIKEN Cell Bank and Clontech, respectively. The U2OS, HCT116, 
and H1299 cells were obtained from ATCC. The HT-29 cells, HCT116 cells, and their 
derivatives were cultured in McCoy’s 5A medium. The RPE cells were cultured in 
DMEM/F-12 medium. The H1299 cells were cultured in RPMI-1640 medium. All other 
cell lines were cultured in DMEM medium. All media were supplemented with 10% 
fetal bovine serum. The RAD54B-KO HCT116 cells were previously described6. 
MG132 (C2211) and cycloheximide (C4859) were obtained from Sigma-Aldrich. 
Oxaliplatin and 5-FU were obtained from Wako. Nutlin-3 and the ATM inhibitor were 
obtained from Millipore. For irradiation, an X-ray generator (Pantak HF 350: 
Shimadzu) was used. For synchronization in the G0/G1 phase, the cells were cultured in 
serum-free medium for two days. The antibodies used in this study are shown in 
Supplementary Table 5. 
 
Plasmids 
The plasmids for FLAG-tag or HA-tag fusion were generated by annealing 
oligonucleotides and ligating these regions to pcDNA3.1/Zeo or pEF4/His (Invitrogen), 
respectively. The plasmid for GFP fusion was generated by PCR amplification followed 
by cloning into the MMTV promoter-based plasmid. The plasmids for full-length 
human Rad54B and Rad54 were previously described25. The plasmid for flow 
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cytometric analyses was generated by inserting the Rad54B coding region into the 
pIRES2-EGFP vector (Clontech). The plasmids encoding full-length human MDM2, 
MDMX, or p53 were cloned by PCR from HEK293 or RPE cell cDNA. The Rad54B, 
MDM2, or MDMX fragment expression plasmids were generated by PCR. The 
sequences of all PCR products were confirmed. For GST-tagged or 6×His-tagged 
proteins, the coding sequence of each protein was ligated to pGEX-5X (GE Healthcare) 
or pET32a (Novagen), respectively. 
 
Plasmid transfection, immunoprecipitation, and Western blot 
The cells were transfected with the indicated plasmids using LipofectamineTM 2000 
reagent (Invitrogen) according to the manufacturer’s instructions. For Western blot, the 
cells were harvested in lysis buffer (0.5% NP-40, 50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 0.5 mM EDTA, 1 mM DTT, 1 mM PMSF, 10 µg ml-1 aprotinin, 50 nM 
cantharidin, and 5 nM Microcystin-LR). For immunoprecipitation, the indicated 
antibody was added to the lysate, and the solution was continuously rotated at 4°C. 
After two hours, the solution was supplemented with Protein G agarose (Invitrogen) and 
rotated for another 1 hour. The beads were washed three times with lysis buffer and 
denatured by boiling in SDS sample buffer. The denatured proteins were resolved by 
SDS-PAGE and transferred to PVDF membrane (Millipore). Immunoblots were 
detected using ECL (GE Healthcare), and the band intensity on the film was quantified 
using Image J software. Full scans of the blots are shown in Supplementary Figs. 11 and 
12. 
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mRNA extraction and quantitative RT-PCR 
Total RNA was extracted using RNAiso Plus (Takara) according to the manufacturer’s 
instructions. Extracted RNA was reverse-transcribed using Moloney murine leukemia 
virus reverse-transcriptase, ribonuclease inhibitor, and random hexamers (Takara). The 
synthesized cDNAs were analyzed for each gene expression level by real-time PCR 
using a Smart Cycler PCR system and SYBR Premix Ex TaqTM (Takara) according to 
the manufacturer’s instructions. The results were quantified relative to a calibration 
curve for each primer set and were normalized to the GAPDH levels. All measurements 
were performed in triplicate. The following primers were used in this study: GAPDH, 
5’-GCACCGTCAAGGCTGAGAAC-3’ (forward) and 
5’-ATGGTGGTGAAGACGCCAGT-3’ (reverse); Rad54B, 
5’-TCCAGGTCTGAATGAAGAGATTAC-3’ (forward) and 
5’-TCTAGTACTTTCTTCACTAGGCAG-3’ (reverse); p53, 
5’-AGATGTTCCGAGAGCTGAATGAG-3’ (forward) and 
5’-GAGAATGTCAGTCTGAGTCAGGC-3’ (reverse); MDM2, 
5’-CCTTAGCTGACTATTGGAAATGC-3’ (forward) and 
5’-ACATCAAAGCCCTCTTCAGCTTG-3’ (reverse); p21, 
5’-GACTCTCAGGGTCGAAAACGG-3’ (forward) and 
5’-GCGGATTAGGGCTTCCTCTTG-3’ (reverse); and Bax, 
5’-ACTCCCCCCGAGAGGTCTT-3’ (forward) and 
5’-GCAAAGTAGAAAAGGGCGACAA-3’ (reverse). 
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siRNA 
All siRNAs were purchased from Dharmacon. Each siRNA (final concentration of 
50-75 nM) was transfected into cells using DharmaFECT4 transfection reagent 
(Dharmacon). For co-transfection of siRNAs and plasmid, siRad54B #2&#3 (final 
concentration of 40 nM each) and pEF-HA-Rad54B 1-467 or SNF2-1 plasmid were 
transfected using DharmaFECT Duo transfection reagent (Dharmacon) according to the 
manufacturer’s instructions. 
 
Production of recombinant proteins 
The GST fusion proteins were expressed in E. coli BL21 cells (GE Healthcare, New 
England BioLabs) and were purified on an Immobilized Glutathione Column (Thermo 
Scientific) or Glutathione Sepharose 4B (GE Healthcare) according to the 
manufacturer’s instructions. The 6×His fusion proteins were expressed in BL21(DE3) 
cells (Invitrogen) and were purified on a TALON resin and a TALON Disposable 
Gravity Column (Clontech). All proteins were dissolved in binding buffer (20 mM 
Tris-HCl (pH 7.4), 10 mM NaCl, and 1 mM MgCl2) using Amicon Ultra-0.5 10K 
(Millipore). If required, the GST tag was removed using Factor Xa (New England 
BioLabs). 
 
GST pull-down assay 
For the GST pull-down assays, the indicated proteins were mixed and incubated at room 
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temperature. After 1-2 hours, the GST-tagged proteins were pulled down using 
Glutathione Sepharose 4B (GE Healthcare) and were eluted in elution buffer (50 mM 
Tris-HCl (pH 8.0) and 10 mM glutathione). The products were resolved by SDS-PAGE 
and immunoblotted using the indicated antibody. 
 
In vitro ubiquitination assay 
In vitro ubiquitination assays were conducted in reaction buffer (50 mM Tris-HCl (pH 
7.4), 5 mM MgCl2, 2 mM ATP, and 2 mM DTT) supplemented with human UBE1 (6 
nM), human UbcH5b (100 nM) (Boston Biochem), in vitro translated p53 (0.3 µl) 
(Promega) and MDM2 (100 ng), in the absence or presence of ubiquitin (25 µM) 
(Boston Biochem), GST-MDMX (200 ng) and His-SNF2-1 (200 ng) at 37°C for 2 hours. 
The reaction was halted by adding SDS sample buffer, and the products were analyzed 
by Western blot. 
 
Cell cycle analysis 
Cells detached using Trypsin-EDTA were fixed if indicated and were stained using a 
CycleTESTTM PLUS DNA Reagent Kit (Becton Dickinson) according to the 
manufacturer’s instructions. Cell cycle analysis was performed using an EPICS XL 
flow cytometer (Beckman Coulter). For the 5-ethynyl-2´-deoxyuridine (EdU) assay, 
EdU (Invitrogen; 10 µM) was added to the medium at the indicated time before 
harvesting. The harvested cells were fixed in 4% paraformaldehyde for 10 minutes and 
were permeabilized using 0.5% Triton-X for 5 minutes at room temperature. After 
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several washes, the incorporated EdU was labeled for 30 minutes by a click chemistry 
reaction in buffer containing 100 mM Tris-HCl (pH 8.0), 1 mM CuSO4, and 10 µM 
Alexa 488 azide (Invitrogen) supplemented with 100 mM ascorbic acid. The labeled 
cells were stained with propidium iodide (PI) and were analyzed as described above. 
 
Immunofluorescence 
The cells cultured on coverslips or detached using Trypsin-EDTA were fixed in 4% 
paraformaldehyde for 10 minutes at room temperature. The cells were permeabilized 
using 0.5% Triton-X and 0.1% SDS for 5 minutes, followed by blocking with 10% 
horse serum for 30 minutes. Then, the cells were incubated in primary antibodies and, 
subsequently, in secondary antibodies at 37°C for 30 minutes. For the cells on 
coverslips, the cells were counterstained with DAPI and mounted. Representative 
images were captured using an Olympus BX51 fluorescence microscope and an 
Olympus DP 70 digital camera equipped with an Olympus DP controller and DP 
manager software. For the detached cells, the cells were analyzed using a FACSAria II  
cell sorter (Becton Dickinson). 
 
Colony formation assay 
The wild-type or RAD54B-KO HCT116 cells were seeded at a density of 6.0 × 103 cells 
per 60 mm dish and were treated with oxaliplatin at the indicated dose. After 7-10 days, 
the cells were fixed and stained to count the colonies. All measurements were 
performed in triplicate. 
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Xenograft model 
All animal experiments were approved by the Institutional Animal Experiment 
Committee of The University of Tokyo. Male BALB/c SIc-nu/nu mice (4 weeks of age) 
were purchased from Nihon SLC (Shizuoka, Japan). Then, 2.5 × 106 wild-type HCT116 
cells or their derivatives were injected subcutaneously. When the tumors reached 
approximately 100 mm3 (Day 0), the mice were intraperitoneally injected with 
oxaliplatin weekly or 5-FU daily at the indicated dose. Tumor growth was measured 
every day after initiation of treatment, and the tumor volume was calculated as 0.5 × 
length × width2. For cell cycle analysis, the oxaliplatin-treated mice were euthanized on 
Day 2 or 3, and the tumors were homogenized for PI staining, which was performed as 
described above. 
 
Analysis of the databases 
Using the raw expression data provided by the GEO database, the average and standard 
deviation of the Rad54B expression levels in normal and tumor samples were calculated 
and were compared using the Mann-Whitney U-test. The average Rad54B expression 
levels in tumor samples were normalized to those in normal samples. The gene datasets 
for p53 mutation status prediction were identified according to the procedure described 
in a previous study23 with some modifications. Briefly, using the gene expression data 
provided by TCGA, the differentially expressed genes between the samples harboring 
wild-type and mutant p53 were identified by excluding those genes displaying a P value 
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on Welch’s t-test >0.001 and by ranking the included genes in decreasing order of the 
log ratio. For hierarchical cluster analyses, the gene expression values were 
mean-centered, and the genes and the samples were clustered by Pearson correlation 
and average linkage (Cluster 3.0 software) to confirm the efficiency of the prediction. 
The clustering results were visualized using Java TreeView software. The samples from 
GEO or REMBRANDT were assigned to the appropriate cluster using the nearest 
neighbor algorithm according to Pearson correlation-based similarity. 
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FIGURE LEGENDS 
Figure 1 | Rad54B constitutes a novel negative-regulatory pathway for p53 
independently of ATM. (a) The responses of Rad54B and p53 expression to oxaliplatin 
treatment in HCT116 cells harboring wild-type p53. Quantification of each protein level 
is shown below. (b) The contribution of p53 to the reduction in Rad54B after DNA 
damage (mean ± s.d.). n.s., not significant; * P<0.05, two-tailed t-test, n=3. (c) The 
effects of DNA damage-independent p53 induction by Nutlin-3 (10 µM) on Rad54B 
protein and mRNA expression (mean ± s.d.). * P<0.05, two-tailed t-test, n=3. (d) 
Western blot for Rad54B after oxaliplatin treatment or IR of HT-29 cells harboring 
mutant p53. (e, f) The Rad54B mRNA levels after IR and the effects of ATM inhibition 
(mean ± s.d.). * P<0.05, two-tailed t-test, n=3. (g) Western blot for p53 after Rad54B 
inhibition. (h) The effects of ATM inhibition on Rad54B-mediated p53 inhibition. (i) 
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Western blot for p53 after DNA damage with Rad54B inhibition. (j) The effects of 
ATM inhibition on Rad54B-mediated p53 inhibition during the DDR. (l) The stability 
of the p53 protein after cycloheximide (CHX) treatment (mean ± s.e.m.; n=3). ** 
P=0.0039, Wilcoxon matched-pairs signed-rank test. (k) The number of γH2AX and 
53BP1 foci-positive cells at the indicated time points after oxaliplatin treatment and 
washing were counted (mean ± s.d.). n.s., not significant; two-tailed Welch’s t-test, n=5 
for each time point. (m) Western blot for ubiquitinated p53 after proteasome inhibition 
using MG132 (10 µM). (n) The MDM2-MDMX complex was analyzed by 
immunoprecipitation after 6 hours of proteasome inhibition using MG132 (10 µM). (o) 
The MDM2-MDMX-mediated ubiquitination-dependent feedback inhibitory loop 
between Rad54B and p53. Rad54B counteracts the canonical ATM kinase-mediated 
pathway during the DDR. 
 
Figure 2 | Rad54B directly interacts with MDM2 and MDMX. (a,b) The 
Rad54B-MDM2 and Rad54B-MDMX interactions were detected in Cos7 cells. (c) The 
interaction between endogenous Rad54B and MDM2. (d) Schematic representation of 
Rad54B and its fragments. The seven conserved helicase-like motifs found in the SNF2 
superfamily are indicated by filled boxes. (e,f) The interaction between the SNF2-1 
domain and MDM2 or MDMX was confirmed by immunoprecipitation in Cos7 cells. 
The arrows indicate each HA-Rad54B fragment, heavy chain (H.C.), or light chain 
(L.C.). (g) The direct interactions were confirmed by pull-down assays. (h) Schematic 
representation of Rad54B mRNA and the targeting region of each siRNA. Notably, 
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neither Rad54B 1-467 nor SNF2-1 expression was interfered using siRNA #2 or #3. (i) 
The effects of supplementation of the Rad54B fragments to the Rad54B-knockdown 
cells were analyzed. (j) Schematic representation of MDM2 and its fragments. (k) The 
interaction between the MDM2 fragments and full-length Rad54B was analyzed by 
immunoprecipitation in Cos7 cells. (l) Schematic representation of MDMX and its 
fragments. (m) The interaction between the MDMX fragment and the Rad54B SNF2-1 
fragment was analyzed by pull-down assays.  
 
Figure 3 | Rad54B enhances p53 ubiquitination by recruiting MDMX to MDM2 and 
promoting MDM2-MDMX heterodimerization. (a) In vitro ubiquitination assays for 
p53. (b) Pull-down assays in which all indicated proteins were included simultaneously. 
The Western blot shown below displays the same amount of MDMX in each product. 
(c) Pull-down assays in which the indicated proteins were pre-incubated for 1 hour. The 
Western blot shown below displays the same amount of MDMX in each product. (d) A 
hypothetical model for the sequence of complex formation in the Rad54B-p53 axis. 
Upon p53 ubiquitination, either p53 is recruited to the Rad54B-MDM2 complex or 
Rad54B is recruited to the p53-MDM2 complex. After formation of the 
Rad54B-MDM2-p53 complex, MDMX is recruited to MDM2 by Rad54B, followed by 
p53 polyubiquitination and degradation. 
 
Figure 4 | Rad54B promotes mutagenic adaptation by dampening p53-dependent 
G2/M checkpoint maintenance. (a) The number of the cells in the G2/M phase after 
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oxaliplatin treatment (mean ± s.e.m.; n=3). Representative diagrams are shown in the 
right panel. n.s., not significant; * P=0.019, two-tailed paired t-test. (b) The cell cycle 
distributions of the cells transfected with the indicated constructs were analyzed by flow 
cytometry. The diagrams shown are representative of three independent experiments. (c) 
The number of G2/M-phase p53-knockdown RAD54B KO cells after oxaliplatin 
treatment was measured at the indicated time points. The graph shown is representative 
of four independent experiments. (d) The oxaliplatin-treated cells were supplemented 
with colcemid (0.1 µg ml-1) 12 hours before measurement of the mitotic index (mean ± 
s.d.). n.s., not significant; ** P<0.001, two-tailed Welch’s t-test, n=5. (e) 
p53-knockdown RAD54B KO cells were analyzed as in (d) (mean ± s.d.). ** P<0.001, 
two-tailed Welch’s t-test, n=10. (f,g) The oxaliplatin-treated wild-type cells were 
supplemented with colcemid 12 hours before fixation and staining with phospho-histone 
H3 (a mitosis marker) and γH2AX (a DNA damage marker). A representative field is 
shown. Scale bar, 10 µm. The arrows indicate the fragmentation of chromosomes. 
 
Figure 5 | Rad54B loosens the DNA damage-induced G1/S checkpoint. (a) Cell 
morphology on the indicated day after oxaliplatin or 5-FU treatment. A representative 
field is shown. Scale bar, 150 µm. (b) The cell cycle distributions after 5-FU treatment. 
The ranges of aneuploid cells are shown below the diagrams. The results are 
representative of three independent experiments. (c) The number of S phase 
p53-knockdown cells after 5-FU treatment was measured. The results are representative 
of three independent experiments. (d,e) The number of G1-arrested cells after DNA 
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damage in Rad54B-overexpressing RPE cells was measured (mean ± s.e.m.; n=3). * 
P<0.05, two-tailed t-test. (f) Serum-starved RAD54B KO cells were released from cell 
cycle arrest by serum addition immediately after IR. The cell cycle distributions were 
analyzed at the indicated time points. The results are representative of four independent 
experiments. (g) Fully confluent Rad54B-knockdown RPE cells were reseeded at low 
density immediately after IR. The cell cycle distributions were analyzed at the indicated 
time points. The results are representative of three independent experiments. (h) 
Nutlin-3 was added eight hours before IR and serum addition. The cell cycle 
distributions were analyzed at the indicated time points. The results are representative of 
three independent experiments. 
 
Figure 6 | Inhibition of Rad54B expression is a feasible strategy for cancer therapy. (a) 
Colony formation assays after oxaliplatin treatment (mean ± s.e.m.; n=4). * P=0.0117, 
two-way ANOVA with repeated measures on the log-transformed cell count, F1,3=30.4. 
(b) The xenograft volume after drug injection was analyzed (mean ± s.d., a semi-log 
scale). The number of mice observed is shown at the right of each line. * P<0.05, ** 
P<0.01, two-tailed Welch’s t-test on the log-transformed rate of xenograft volume 
growth. (c) The cell cycle distributions of the representative xenografts at the indicated 
time points were analyzed. (d) The Rad54B levels in the neoplastic samples (means ± 
s.d.). The number of samples analyzed is shown in Supplementary Table 1. The average 
Rad54B levels in tumor samples were normalized to those in normal samples. * P<0.05, 
** P<0.01, Mann-Whitney U-test. (e) The paired Rad54B expression data between 
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normal and colorectal adenoma samples from the same patient. See also Supplementary 
Table 1. (f) The survival datasets from REMBRANDT. Elevated expression was 
defined as a 2-fold or greater increase in Rad54B expression. The points in the graph 
correspond to the censored cases. For a detailed description, see the REMBRANDT 
website. ** P<0.001, log-rank test. 
 
Figure 7 | Schematic summary of this study in terms of the time course and cell cycle. 
(a) The scaffold protein Rad54B causes the latency of p53-mediated checkpoint 
activation. During the early phases of the DDR, Rad54B constitutes the 
ATM-independent negative-regulatory DDR pathway. (b) The Rad54B-p53 axis 
regulates the checkpoint strength. Elevated expression of Rad54B induces checkpoint 
override, thereby enhancing genomic instability, mutagenesis and drug resistance. 
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Supplementary Figure 1 | Rad54B is a novel DNA damage-responsive protein.
(a) The responses of Rad54B and p53 to IR in HCT116 cells. (b) The involvement of p21 in p53-mediated 
Rad54B repression was analyzed by RT-PCR (mean ± s.d.). n.s., not significant; * P<0.05, two-tailed t-test, 
n=3. (c,d) The responses of Rad54B upon DNA damage in H1299 cells (mean ± s.d.; n=3). (e,f) The levels 
of Rad54B mRNA after oxaliplatin treatment with or without ATM inhibition in HT-29 cells (mean ± s.d.; 
n=3). (g) The effects of Rad54B or MDM2 knockdown on the p53 levels. (h) The expression of p53 target 
genes in the steady state in Rad54B-knockdown cells (mean ± s.e.m.; n=4). 
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Supplementary Figure 2 | Rad54B downregulates the p53 levels and functions after DNA damage. 
(a,b) Western blots for p53 after genotoxic stresses with Rad54B inhibition. (c) The expression of p53 target 
genes in Rad54B-knockdown cells after oxaliplatin treatment (mean ± s.d.; n=3). (d) The levels of p53, 
ATM, and ATR with modification upon oxaliplatin treatment were analyzed at the indicated time points by 
Western blot. (e) The number of ?H2AX and 53BP1 foci-positive A549 cells at the indicated time points 
after oxaliplatin treatment and wash was counted (mean ± s.d.). n.s., not significant, two-tailed Welch’s 
t-test, n=5 for each time point. 
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Supplementary Figure 3 | Rad54B reduces the stability of p53 by enhancing MDM2-MDMX 
heterodimerization. 
(a) The effects of Rad54B on p53 stability in A172 cells (mean ± s.e.m.; n=3). ** P=0.0039, Wilcoxon 
matched-pairs signed-rank test. (b) p53 ubiquitination after proteasome inhibition was analyzed in parallel 
with p53 knockdown. Notably, the ubiquitinated materials observed here are derived from p53. (c) 
Rad54B-knockdown A549 cells were fixed and stained with an antibody against MDM2 (Red) and with 
DAPI (DNA; blue). Scale bar, 10 ?m. (d) The MDM2-p53 interaction was analyzed by immunoprecipitation 
with an antibody against p53. To adjust the p53 levels in the lysate, the indicated amount of lysate from 
Rad54B-knockdown A549 cells was used. The Western blot shown below displays the same amount of p53 
in the 10% input sample. (e,f) The MDM2-MDMX complex formation following MDM2 knockdown (e) or 
with DNA damage (f) was analyzed by immunoprecipitation after 6 hours of proteasome inhibition. The 
relative MDMX levels in the immunoprecipitate normalized to the input levels are shown. 
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Supplementary Figure 4 | Rad54B interacts with MDM2 and MDMX.  
(a,b) The interaction between endogenous Rad54B and MDM2 was detected by immunoprecipitation. (c) 
The interaction between endogenous Rad54B and MDMX was detected in the nuclear extract after 
proteasome inhibition. (d) The Rad54B levels after proteasome inhibition and protein synthesis inhibition 
were analyzed by Western blot. (e) The interaction between Rad54 and MDM2 was not detected in HCT116 
cells. (f) The purity of the recombinant proteins used in this study was confirmed by Coomassie staining. 
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IR was measured. The results are representative of more than three independent experiments. (c) The p53 
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Supplementary Figure 6 | Rad54B is involved in G1/S checkpoint maintenance.  
(a) The number of G1-phase and S-phase cells after oxaliplatin treatment was measured at the indicated time 
points. The results are representative of three independent experiments. (b) The number of S-phase cells 
after 5-FU treatment was measured in Rad54B-knockdown LoVo cells. The results are representative of 
three independent experiments. (c) The p21 levels after 5-FU treatment were analyzed in both 
Rad54B-knockdown LoVo cells and RAD54B KO cells. (d) The diagrams for EdU-incorporated S-phase 
cells after 5-FU treatment (upper panel) and the cell cycle distributions of whole cells (lower panel) are 
shown. The arrows indicate the early S-phase cells. The results are representative of three independent 
experiments. (e,f) The p53 levels in the Rad54B-overexpressing RPE cells after 5-FU (e) or oxaliplatin (f) 
treatment were analyzed by flow cytometry. The results are representative of more than three independent 
experiments. (g) The cell cycle progression of RPE cells after release from contact inhibition was analyzed. 
The results are representative of three independent experiments. 
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Supplementary Figure 8 | Prediction of the p53 mutation status of the colon adenoma samples based on 
the gene expression patterns. 
(a) TCGA COAD samples were clustered according to the expression patterns of the gene set identified 
using the algorithm described in the Methods section. (b) GDS2947 samples were assigned to the cluster 
defined in (a) according to Pearson correlation-based similarity. Notably, Rad54B expression was higher in 
adenoma samples than in normal samples, regardless of the predicted p53 status. See also Supplementary 
Table 3. 
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Range Molecular state/treatment Cellular level outcome Clinical/in vivo outcome 
MDM2 KO Extensive apoptosis Lethality
MDMX KO
and cell cycle arrest
Normal
Rad54B overexpression Increase in adaptation (checkpoint escape)
Mutation in p53 Defects in DDR, abberant proliferation
Malignant conversion 
and progression
MDM2 overexpression Decrease in apoptosis
Nutlin-3 Increase in apoptosis Anti-tumor effects with adverse effects
Mutagenesis/drug resistance
Toxic
Effective
Mutagenic
Oncogenic
p53 functions
RAD54B KO/KD Suppression of drug resistanceSuppression of checkpoint escape
Supplementary Figure 10 | The outcomes of changes in the p53 levels. 
Fig. 1a
Fig. 1c
Fig. 1d
Fig. 1g
Fig. 1h Fig. 1i
Fig. 1j Fig. 1l
Fig. 1m
Fig. 1n
Fig. 2a Fig. 2b Fig. 2c
Fig. 2e
Fig. 2f Fig. 2g Fig. 2i
Fig. 2k
Fig. 2m
Fig. 3a Fig. 3b Fig. 3c
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
10 kDa -
15 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
- 100 kDa
- 75 kDa
- 50 kDa 
- 37 kDa
- 150 kDa
- 250 kDa
- 25 kDa
- 20 kDa
- 100 kDa
- 75 kDa
- 50 kDa 
- 37 kDa
- 150 kDa
- 250 kDa
- 25 kDa
- 20 kDa
- 100 kDa
- 75 kDa
- 50 kDa 
- 37 kDa
- 150 kDa
- 250 kDa
- 25 kDa
- 20 kDa
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
10 kDa -
15 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
15 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
15 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
- 100 kDa
- 75 kDa
- 50 kDa 
- 37 kDa
- 150 kDa
- 250 kDa
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
20 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
25 kDa -
20 kDa -
15 kDa -
10 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
25 kDa -
20 kDa -
15 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
25 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
37 kDa -
150 kDa -
250 kDa -
100 kDa -
75 kDa -
50 kDa -
150 kDa -
250 kDa -
150 kDa -
250 kDa -
Supplementary Figure 11 | Full scans of the blots in Figs. 1-3. 
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Supplementary Figure 12 | Full scans of the blots in Supplementary Figs. 1-4,6. 
Supplementary Table 1 | Comparison of the Rad54B expression levels between the 
normal and neoplastic samples from the GEO database.  
 
Organ, type 
Sample number Relative Rad54B levels 
Mann-Whitney 
U-test 
NCBI 
Accession 
Number normal tumor normal tumor P value 
Acute myeloid leukemia 38 26 1±0.12 1.00±0.10 0.309 GDS3057 
Lymphoma 20 42 1±0.16 0.99±0.16 0.982 GDS3516 
Papillary thyroid 7 7 1±0.19 1.05±0.12 0.798 GDS1732 
Breast 7 40 1±0.12 **1.43±0.23 0.0001 GDS2250 
Cervix 24 28 1±0.41 **2.09±0.87 <0.0001 GDS3233 
Cutaneous melanoma 7 45 1±0.46 *1.54±0.52 0.0147 GDS1375 
Lung adenocarcinoma 49 58 1±0.03 **1.09±0.08 <0.0001 GDS3257 
Ovarian adenocarcinoma 12 12 1±1.21 *2.60±1.82 0.0141 GDS3592 
Oral squamous carcinoma 4 16 1±1.01 *3.17±1.63 0.0160 GDS1584 
Sarcoma 15 39 1±0.54 **2.60±1.44 <0.0001 GDS1209 
Vulvar intraepithelial neoplasia 9 9 1±0.48 **2.26±0.63 0.0011 GDS2418 
 
 
 
Organ, type 
Patient 
number 
Relative Rad54B levels Rad54B levels Tumor displaying 
elevated Rad54B 
expression 
NCBI 
Accession 
Number normal (N) tumor (T) T > N T ? N 
Colorectal adenoma 32 1±0.46 3.97±0.92 32 0 100% GDS2947 
Lung squamous carcinoma 5 1±0.02 1.08±0.06 4 1 80% GDS1312 
mean ± s.d., * P<0.05, ** P<0.01, Mann-Whitney U-test. 
Supplementary Table 2 | Prediction of the p53 mutation status of the GDS2250 samples.  
 
Database Cluster 
p53-mutated samples 
in each cluster 
Risk of p53 mutation
a
  
TCGA BRCA (N=590) 
1-243 139  57.2% 
 
244-590 27  7.8% 
Database 
Group 
Cluster 
Number of samples in 
each cluster
b 
(%
 
total) 
Predicted number of 
p53-mutated samples 
for each cluster
*
 
Predicted number of 
p53-mutated samples 
for group (%
 
total) 
GDS2250 
Normal (N=7) 
1-243 0 (0%) 0 
0.5 (7.8%) 
244-590 7 (100%) 0.5 
GDS2250 
Cancer (N=40) 
1-243 28 (70%) 16 
17.0 (42.3%) 
244-590 12 (30%) 0.9 
* calculated as (a) × (b). 
Supplementary Table 3 | Prediction of the p53 mutation status of the GDS2947 samples. 
 
Database Cluster 
p53-mutated samples 
in each cluster 
Risk of p53 mutation
a
  
TCGA COAD (N=174) 
1-26 15  57.7% 
 
27-174 0  0% 
Database 
Group 
Cluster 
Number of samples in 
each cluster
b 
(%
 
total) 
Predicted number of 
p53-mutated samples 
for each cluster
*
 
Predicted number of 
p53-mutated samples 
for group (%
 
total) 
GDS2947 
Normal (N=32) 
1-26 1 (3.1%) 0.6 
0.6 (1.8%) 
27-174 31 (96.9%) 0 
GDS2947 
Adenoma (N=32) 
1-26 5 (16%) 2.9 
2.9 (9.0%) 
27-174 27 (84%) 0 
* calculated as (a) × (b). 
Supplementary Table 4 | Prediction of the frequency of the REMBRANDT samples carrying a p53 mutation. 
 
Database Cluster 
p53-mutated samples 
in each cluster 
Risk of p53 mutation
a
  
TCGA GBM (N=595) 
1-186 49  26.3% 
 187-310 19  15.3% 
311-595 15  5.3% 
Database 
Group 
Cluster 
Number of samples in 
each cluster
b 
(%
 
total) 
Predicted number of 
p53-mutated samples 
for each cluster
*
 
Predicted number of 
p53-mutated samples 
for group (%
 
total) 
REMBRANDT 
Rad54B low (N=135) 
1-186 56 (41.5%) 14.8 
20.4 (15.1%) 187-310 15 (11.1%) 2.3 
311-595 64 (47.4%) 3.4 
REMBRANDT 
Rad54B high (N=223) 
1-186 97 (43.5%) 25.6 
34.0 (15.2%) 187-310 18 (8.1%) 2.8 
311-595 108 (48.4%) 5.7 
* calculated as (a) × (b). 
Supplementary Table 5 | Antibodies used in this study.  
Source/reference Antibody Dilution 
Ref. 10 Rabbit polyclonal anti-Rad54B 1:500 for Western blot 
Bethyl Laboratories, Inc.  Goat polyclonal anti-MDMX (A303-870A) 1:500 for Western blot 
Cell Signaling Technology Acetyl-p53 (Lys382) (#2525) 1:500 for Western blot 
 Phospho-ATM (Ser1981) (#4526) 1:500 for Western blot 
 Phospho-p53 (Ser15) (#9284) 1:500 for Western blot 
 Phospho-p53 (Ser20) (#9287) 1:500 for Western blot 
GeneTex ATR (phospho Thr1989) (GTX128145) 1:500 for Western blot 
Jackson ImmunoResearch R-phycoerythrin-conjugated anti-mouse 
IgG (115-116-146) 
1:100 for flow cytometry 
MBL Multi Ubiquitin FK2 (D058-3) 1:500 for Western blot 
 Annexin V-FITC (4700-100) 1:10 for flow cytometry 
Millipore MDM2 2A10 (OP115) 1:500 for Western blot 
 MDMX 8C6 (#04-1555) 1:500 for Western blot 
 p53 Binding Protein 1 (PC712) 1:500 for immunofluorescence 
 Phospho-Histone H2A.X (Ser139) (#05-636) 1:500 for immunofluorescence 
 Phospho-Histone H3 (Ser 10) (#06-570) 1:500 for immunofluorescence 
Novus Biologicals Rabbit polyclonal anti-ATM (NB100-104) 1:500 for Western blot 
Santa Cruz Biotechnology ATR N-19 (sc-1887) 1:500 for Western blot 
 Cdk2 M2 (sc-163) 1:1,000 for Western blot 
 MDM2 SMP14 (sc-965) 1:200 for Western blot 
2?g for immunoprecipitation 
1:200 for immunofluorescence 
 p21 187 (sc-817) 1:200 for Western blot 
 p53 DO-1 (sc-126) 1:1,000 for Western blot 
1?g for immunoprecipitation 
1:100 for flow cytometry 
 Rad54B 19-K2 (sc-101234) 1:100 for Western blot 
1?g for immunoprecipitation 
Sigma Aldrich  ?-Actin AC-15 (A5441) 1:10,000 for Western blot 
 FLAG M2 (F3165, F1804) 1:1,000 for Western blot (F3165) 
1?g for immunoprecipitation (F1804) 
 HA-7 (H6533, H9658) 1:1,000 for Western blot (H6533) 
1?g for immunoprecipitation (H9658) 
